Trevi Therapeutics is advancing nalbuphine ER (Haduvio) for chronic cough in IPF and RCC, with strong Phase 2 efficacy in IPF. TRVI's valuation reflects optimism, but the risk/reward profile and ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果一些您可能无法访问的结果已被隐去。
显示无法访问的结果